Edwards Lifesciences (EW) shares swoone⛄d Thursday, dropping after the company damped expectations for heart valve replacement sales growth o🍰n Wednesday.

The company said it expects full-year sales growth of 5% to 7% for its transcatheter aortic valve replacement (TAVR) treatment, down from the 8% to 10% forecast earlier. TAVR involves replacing a diseased heart valve using a catheter rather than through open-heart surgery.

Full-year sales of transcatheter mitral and tricuspid therapies (TMTT) are expected to come in on the higher end of Edwards’ previous🗹ly issued range of $320 million to $340 million. The company reiterated its surgical sales growth projection of 6% to 8%. 

Shares of Edwards plunged 31% to finish at $59.76 Thursday, leaving them down about 22% this year. The stock was the day's worst performer in the 澳洲幸运5开奖号码历史查询:S&P 500.

In the second quarter, Edwards posted 澳洲幸运5开奖号码历史查询:earnings per share (EPS) of 61 cents, falling short of t🍒he 74 cents expected by analysts, according to Visible Alpha. Revenue was $1.39 billion, below expectations. TAVR revenue rose 5% year-over-year to $1 billion.